Synergistic Efficacy of Dual-Target HSA-Based Delivery for HER and VEGFR Co-Blockade in Triple-Negative Breast Cancer
{{output}}
Resistance to monotherapies targeting receptor tyrosine kinases remains a major challenge in triplenegative breast cancer (TNBC). Here, we developed a dualtarget HSAbased nanobioconjugate combining human serum albumin (HSA)-encapsulated lapatinib, an EGFR1/2 i... ...
